CCM
DNA icon

CAAS Capital Management’s Ginkgo Bioworks DNA Stock Holding History

CAAS Capital Management’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-7,450
Closed -$504K – 760
2022
Q4 		$504K Buy
+7,450
New +$685K 0.03% 439

Other funds holding DNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
GA
General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return

CAAS Capital Management's DNA Position: Q1 2023 in Review

CAAS Capital Management sold out of Ginkgo Bioworks (DNA) in Q1 2023, closing a stake of 7,450 shares — an estimated $504K sold.

CAAS Capital Management first reported a position in DNA in Q4 2022 and held it in 1 quarter. The position peaked at $504K in Q4 2022. 313 funds tracked by Wall St. Rank hold DNA as of Q1 2023.

  • CAAS Capital Management reported no remaining Ginkgo Bioworks position as of Q1 2023 after selling out during the quarter.
  • CAAS Capital Management sold 7,450 Ginkgo Bioworks shares in Q1 2023, an estimated $504K.
  • CAAS Capital Management first reported a position in Ginkgo Bioworks in Q4 2022 and held it in 1 quarter.
  • CAAS Capital Management's Ginkgo Bioworks position peaked at $504K in Q4 2022.
  • 313 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2023.

Based on CAAS Capital Management's 13F filing for Q1 2023, filed 15 May 2023.